FDAnews
www.fdanews.com/articles/101992-gsk-galapagos-ink-agreement

GSK, Galapagos Ink Agreement

December 10, 2007

UK drugmaker GlaxoSmithKline (GSK) and Belgium’s Galapagos have signed an agreement to develop anti-infective drug candidates.

Under the terms of the agreement, Galapagos will grant GSK options to license product candidates against up to six anti-infective discovery targets. Galapagos will be responsible for the development of small molecule drug candidates to clinical proof of concept.

GSK, which will participate in the alliance through its Infectious Diseases Center of Excellence for Drug Discovery, will have exclusive option to license each compound for worldwide development and commercialization on a worldwide basis, according to GSK.